Comparison of Tumor Necrosis Factor-α Level in Coronary Artery Disease and Coronary Slow Flow of Thrombolysis in Myocardial Infarction

Muhammad Diah, Rahmawati Rahmawati, Aznan Lelo, Zulfikri Muhktar, Dharma Lindarto, Ferry Sandra


BACKGROUND: Tumor necrosis factor (TNF)-α, an important primary pro-inflammatory cytokine, has a crucial role in the pathogenesis of atherosclerosis. Since the pathophysiological mechanism of coronary slow flow (CSF) is not fully understood, we investigated the level of TNF-α in coronary artery disease (CAD), CSF and healthy subjects.

METHODS: This study was conducted in cross-sectional design involving 16 CAD, 18 CSF and 18 healthy subjects. Coronary angiography was recorded at the left anterior oblique, cranial, right anterior oblique, caudal, and horizontal positions. The flow in coronary arteries of the subjects were assessed using Thrombolysis in the Myocardial Infarction (TIMI) frame count method. Peripheral blood-derived serum was collected and level of TNF-α was determined by using highly sensitive enzymelinked immunosorbent assay (ELISA).

RESULTS: No significant difference in level of TNF-α in CAD, CSF and healthy subjects (2.72±2.64 pg/mL, 1.88±0.8 pg/mL, 1.64±0.35 pg/mL, respectively) (p=0.087). In addition, there was no correlation between the concentration of TNF-α and TIMI frame count (r<0.2, p>0.05).

CONCLUSION: There was no significant difference of TNF-α level in CAD, CSF and healthy subjects. In addition, there was no correlation between the TNF-α level with TIMI frame count as well. Nevertheless, further clinical studies with more subjects are needed.

KEYWORDS: TNF-alpha, coronary artery disease, coronary slow flow


Full Text:



Javed Q. Clinical implications of tumor necrosis factor-alpha, interleukin-6 and resistin in coronary artery disease. World J Cardiovasc Dis. 2014; 4: 416-21, CrossRef.

Padfield GJ, Din JN, Koushiappi E, Mills NL, Robinson SD, Lucking AJ, et al. Cardiovascular effects of tumour necrosis factor α antagonism in patients with acute myocardial infarction: a first in human study. Heart. 2013; 99: 1330-5, CrossRef.

Rosenson RS, Koenig W. Utility of inflammatory markers in the management of coronary artery disease. Am J Cardiol. 2003; 92(Suppl): 10i-8i, article.

Hou L, Huang J, Lu X, Wang L, Fan Z, Gu D. Polymorphisms of tumor necrosis factor alpha gene and coronary heart disease in a Chinese Han population: Interaction with cigarette smoking. Thromb Res. 2009; 123: 822-6, CrossRef.

Gotsman A, Stabholz D, Planer D, Pugatsch T, Lapidus L, Novikov Y, et al. Serum cytokine tumor necrosis factor-alpha and interleukin-6 associated with the severity of coronary artery disease: indicators of an active inflammatory burden? Isr Med Assoc J. 2008; 10: 494-8, PMID.

Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996; 93: 879-88, CrossRef.

Yilmaz H, Demir I, Uyar Z. Clinical and coronary angiographic characteristics of patients with coronary slow flow. Acta Cardiol. 2008; 63: 579-84, CrossRef.

Hawkins BM, Stavrakis S, Rousan TA, Schechter E. Coronary slow flow -- prevalence and clinical correlations. Circ J. 2012; 76: 936-42. Hawkins BM, Stavrakis S, Rousan TA, Schechter E. Coronary slow flow prevalence and clinical correlations. Circ J. 2012; 76: 936-42, CrossRef.

Hua XP, Zhang XD, Kwong JSW, Zeng XT, Zhang ZJ, Wei WL. Tumor necrosis factor-alpha G-238Apolymorphism and coronary artery disease risk: a meta-analysis of 4,222 patients and 4,832 controls. Ther Clin Risk Manag. 2015:11; 1429-36, CrossRef.

Razi MM, Abdali N, Asif SM, Azharuddin M. Association of inflammatory cytokines/biomarkers with acute coronary syndrome and its correlation with severity and hospital outcome. J Clin Prev Cardiol. 2017; 6: 44-9, article.

Fichtlschereh S, Heeschen C, Zeiher AM. Inflammatory markers and coronary artery disease. Curr Opin Pharmacol. 2004; 4: 124-31, PMID.

Tian M, Yuan YC, Li JY, Gionfriddo MR, Huang RC. Tumor necrosis factor-a and its role as a mediator in myocardial infarction: A brief review. Chronic Dis Transl Med. 2015; 1: 18-26, CrossRef.

Nikolic VN, Stoimenov TJ, Stokanovic D, Milovanovic M, Radovanovic RV, Pesic S, et al. An inverse correlation between TNF alpha serum levels and heart rate variability in patients with heart failure. J Cardiol. 2013; 62: 37-43, CrossRef.

Skoog T, Dichtl W, Boquist S, Skoglund-Andersson C, Karpe F, Tang R, et al. Plasma tumor necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J. 2002; 23: 376-83, CrossRef.

Sukhija R, Fahdi I, Garza L, Fink L, Scott M, Aude W, et al. Inflammatory markers, angiographic severity of coronary artery disease, and patient outcome. Am J Cardiol. 2007; 99: 879-84, CrossRef.

Dai YX, Li CG, Huang ZY, Zhong X, Qian JY, Liu XB, et al. Clinical and angiographic characteristics of patients with slow coronary flow. Zhonghua Xin Xue Guan Bing Za Zhi. 2011; 39: 642-6, PMID.

Mukhopadhyay S, Kumar M, Yusuf J, Gupta VK, Tyagi S. Risk factors and angiographic profile of coronary slow flow (CSF) phenomenon in North Indian population: An observational study. Indian Heart J. 2018; 70: 405-9, CrossRef.

Sezgin AT, Sigirci M, Barutcu I. Vascular endothelial function in patients with slow coronary flow. Coron Artery Dis. 2003; 14: 155-61, CrossRef.

Sezgin N, Barutcu I, Sezgin AT, Gullu H, Turkmen M, Esen AM, et al. Plasma nitric oxide level and its role in slow coronary flow phenomenon. Int Heart J. 2005; 46: 373-82, CrossRef.


Indexed by:






The Prodia Education and Research Institute